New Clinical Drug Evaluation Unit (NCDEU) Annual Meeting: A Great Opportunity for Early Career Psychiatrists
J Clin Psychiatry 2012;73(4):504-505
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
When the Early Clinical Drug Evaluation Unit meeting was first held over a half century ago, psychopharmacology and indeed modern-day psychiatry were in their infancy, yet there was enormous excitement surrounding the introduction of new medications that appeared to have a profound impact on major psychiatric illnesses. Perhaps the most publicized effect was the control of the florid symptoms of psychosis that was used as a basis for moving the majority of patients with schizophrenia to outpatient settings as an alternative to long-term hospitalizations. Even then, it was realized that much more needed to be done and that it was in the public interest for government to invest in methods for developing effective treatments for serious mental illnesses.
J clin Psychiatry2012; 73(4):504-505
© 2012 Physicians Postgraduate Press, Inc.